XTL Biopharmaceuticals
Sector: Healthcare & Life Sciences
About XTL Biopharmaceuticals
Focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. (NASDAQ:XTLB), (TASE:XTLB.TA)
Products
hCDR1 - Systematic Lupus Erythematosus, Recombinant Human Erythropoietin (rHuEPO) - Multiple Myeloma
The XTLbio pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates with advantages over current therapies and which address unmet medical needs. Today 3 compounds are actively being developed, all in clinical stages.